Core Insights - Clover Health Investments, Corp. will release its financial results for the third quarter of 2025 on November 4, 2025, after market close [1] - A webcast presentation will be held at 5:00 p.m. Eastern Time on the same day to discuss the company's performance [1][4] Company Overview - Clover Health is a physician enablement technology company focused on providing access to quality healthcare for Medicare recipients, particularly seniors [3] - The company utilizes its software platform, Clover Assistant, to aggregate patient data and support clinical decision-making, aiming to improve health outcomes and manage chronic diseases [3] - Clover Health offers PPO and HMO Medicare Advantage plans across several states, emphasizing its wide-network, high-choice PPO plans [3] - The company also extends its data-driven technology through its subsidiary, Counterpart Health, to enhance patient outcomes and reduce healthcare costs nationwide [3] - Clover Health has published data showing the positive impact of its technology on various health conditions, including Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes, and Chronic Kidney Disease [3]

Core Points - CareCloud, Inc. has declared monthly cash dividends for its Series A and Series B Preferred Stocks for the last quarter of 2025 [1] - The dividends for Series A and Series B are set at 8.75% per annum based on a $25.00 liquidation preference [2][3] Dividend Details - Series A dividend per share for October, November, and December 2025 is $0.18229, with additional payments of $0.04688 for October and $0.01719 for November [2] - Series B dividend per share for the same months is also $0.18229 [2] - Ex-dividend and record dates for all dividends are the last day of each month, with payment dates scheduled for mid-November, mid-December, and mid-January [2][4] Additional Information - Series A Preferred Stock was converted to common stock on March 6, 2025, and holders of these shares will not receive further dividends [3] - The Series B Preferred Stock is still trading on the Nasdaq Global Market under the ticker symbol "CCLDO" [6] - CareCloud's suite of healthcare technology solutions aims to enhance financial and operational performance for over 40,000 providers [8]

Core Insights - Aclarion, Inc. has been selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH, highlighting its innovative contributions to healthcare technology [1][4]. Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary AI algorithms to enhance clinical treatments [7]. - The company's flagship product, Nociscan, is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [3][7]. Product Details - Nociscan transforms MR spectroscopy signals into objective biomarkers associated with disc pain, providing actionable insights for personalized treatment plans [3][7]. - An estimated 266 million people globally suffer from chronic low back pain, indicating a significant market opportunity for Aclarion's solutions [3]. Recognition and Impact - The recognition as a finalist from over 1,800 submissions underscores Aclarion's commitment to improving healthcare efficiency and equity through digital innovations [4][6]. - CEO Brent Ness emphasized that this acknowledgment reflects the company's vision and determination to make Nociscan widely available to those affected by chronic low back pain [4].

Company Movements - Spruce Biosciences, Inc. experienced a monumental surge, with its price jumping to $136.81, marking a 1451% increase due to the FDA granting Breakthrough Therapy Designation for its tralesinidase alfa enzyme replacement therapy for treating Sanfilippo Syndrome Type B [1][7] - OneMedNet Corporation Warrants saw its price increase by 233.17% to $0.19, related to a strategic partnership with Palantir Technologies to enhance its healthcare AI and data analytics capabilities [2][7] - OneMedNet Corporation also made notable gains, with its price escalating by 184.88% to $2.93, driven by investor optimism around its technology and the partnership with Palantir Technologies [3][7] - Society Pass Incorporated experienced a 146.18% increase in its price to $3.47, following an analyst upgrade based on the company's robust second-quarter performance and positive future outlook [4][7] - Argo Blockchain plc saw its price rise by 106.89% to $0.86, despite uncertainty over its financial future, linked to ongoing negotiations regarding a senior secured loan crucial for its recapitalization plan [5][7] Market Dynamics - The significant price movements of these companies underscore the diverse factors at play in the financial markets, including technological innovations, clinical advancements, and strategic corporate actions [6][7]

Core Insights - OneMedNet Corp has partnered with Palantir Technologies to enhance its healthcare AI and real-world data analytics capabilities, aiming to tap into the $868 billion AI healthcare market by 2030 [1][4] - The collaboration will utilize Palantir's Artificial Intelligence Platform to integrate complex datasets and provide real-time insights, connecting with OneMedNet's extensive network [2][3] - The partnership will focus on key therapeutic areas such as oncology, cardiology, and rare diseases, providing access to over 5 billion administrative claims and 131 million clinical exams [3] Company Developments - OneMedNet's use of Palantir's platform will enable the delivery of high-quality, regulatory-compliant data at remarkable speed, facilitating breakthroughs in clinical research and AI-driven healthcare solutions [4] - Following the announcement, OneMedNet's shares surged by 46.60%, reaching $1.510 in premarket trading [4]

Core Insights - TruBridge has appointed Michael Daughton as Chief Business Officer effective October 6, 2025, to enhance client-centered excellence and growth [1] Company Overview - TruBridge is a leading provider of revenue cycle management and healthcare technology solutions specifically for rural and community healthcare organizations [1]

A recent acquisition seems to be paying off already for the tech-forward healthcare data specialist.What a difference a week can make on the stock market. Next-generation healthcare tech company Tempus AI's (TEM 1.49%) stock was doing quite well, thank you very much, over the past few days, in contrast to the preceding five-day trading stretch. Due to some positive news from a subsidiary brought into its portfolio recently, this week to date (as of early Friday morning) Tempus AI's shares were rising by alm ...

Core Insights - Doximity (DOCS) reported first-quarter revenues of $145.9 million, reflecting a 15% year-over-year increase, with an adjusted EBITDA margin of 55% [1][4] - The company is focusing on artificial intelligence as a key component of its strategy, highlighted by the launch of Doximity AI Scribe and the acquisition of Pathway [1][5] Financial Performance - Free cash flow increased by 52% year over year, and net revenue retention remained strong at 118% [4] - Management anticipates an 11% revenue growth for fiscal 2026, despite some caution regarding policy-driven uncertainties [4] AI Initiatives - Doximity AI Scribe has over 10,000 beta testers, with 75% using the tool weekly, which aims to reduce after-hours documentation burdens for physicians [2][9] - The $26 million acquisition of Pathway enhances Doximity's clinical AI capabilities, introducing a proprietary medical corpus that scored 96% on the U.S. medical licensing exam [3][9] Competitive Landscape - Other companies, such as Certara and GE HealthCare, are also developing AI tools to enhance their offerings, with Certara's software revenues rising 22% year over year to $46 million [7] - GE HealthCare has invested significantly in R&D for AI integration across its products, showcasing new AI-enabled diagnostics and planning to launch nearly 200 AI/ML-enabled devices in the next three years [8]

Core Insights - Doximity, Inc. is recognized as a leading healthcare technology stock, utilizing AI-driven tools and strategic acquisitions to enhance its market position [1] - The recent acquisition of Pathway Medical significantly improves Doximity's DoxGPT tool, providing instant access to verified medical data and AI responses [2] - Doximity has introduced Doximity Scribe, an AI tool that automates clinical documentation, thereby reducing administrative workload for clinicians [3] Financial Performance - In the last quarter ending June 30, 2025, Doximity reported a 15% year-over-year revenue increase, reaching $145.9 million, surpassing analyst expectations [4] - The company achieved non-GAAP earnings per share (EPS) of $0.36, indicating strong financial performance [4] - User engagement and product adoption have notably increased, particularly for new AI scribe and workflow tools [4]

MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of advanced healthcare AI solutions, today announced that it has secured access to the International Skin Imaging Collaboration (ISIC) Archive - one of the world's largest publicly available, biopsy-verified image repositories for skin cancer and related dermatological conditions. The ISIC Archive contains more than 70,000 high-quality, expertly annotated dermoscopic images, representing ...